How Wegovy vs Mounjaro Doses Compare for UK Patients
Understanding Wegovy vs Mounjaro Doses for Prescription Weight Loss
When comparing Wegovy vs Mounjaro doses, the fundamental difference lies in their mechanisms and escalation schedules. Wegovy (semaglutide) follows a 5-step dose escalation over 16 weeks, starting at 0.25mg and reaching the maintenance dose of 2.4mg weekly. Mounjaro (tirzepatide) uses a 4-step escalation beginning at 2.5mg and potentially reaching 15mg weekly. Both are prescription-only medicines requiring clinical assessment and ongoing medical supervision.
The dosing philosophy differs significantly between these treatments. Wegovy's gradual escalation allows patients to adjust slowly to the GLP-1 receptor effects, while Mounjaro's dual GIP and GLP-1 receptor approach starts at a higher equivalent dose. Neither approach is inherently superior—your prescriber will consider your medical history, weight management goals, and tolerance when determining which Wegovy vs Mounjaro doses pathway suits your individual needs. Both treatments must be used alongside a reduced-calorie diet and increased physical activity for optimal results.
Wegovy vs Mounjaro Doses: UK Pricing and Value Comparison
At EverydayMeds, Wegovy doses are priced transparently: 0.25mg starter dose costs £79.99, escalating to £94.99 for 0.5mg, £99.99 for 1mg, £139.99 for 1.7mg, and £209.99 for the 2.4mg maintenance dose. Our Intro Duo bundle (0.25mg & 0.5mg) provides the first 8 weeks of treatment for £169.99. New customers apply discount code FIRST40 at checkout, while returning customers use DOSE25 to reach these final prices.
When comparing Wegovy vs Mounjaro doses financially, consider the total cost over your treatment duration rather than individual pen prices. Wegovy's longer dose escalation period means more pen purchases initially, but this gradual approach may support better tolerance. Our Bundle options like the Intro Trio (0.25mg, 0.5mg & 1mg) for £299.99 provide convenience and Reliable Supply continuity. Both treatments require ongoing monthly costs, making it essential to discuss long-term affordability with your prescriber during your clinical assessment.
Clinical Evidence Behind Wegovy vs Mounjaro Doses
The STEP clinical trial programme demonstrates Wegovy's efficacy across its dose escalation schedule. In STEP 1, patients taking Wegovy alongside diet and exercise achieved an average of approximately clinically studied weight loss at 68 weeks compared to 2.4% with placebo (Wilding et al., NEJM, 2021). The 2.4mg maintenance dose showed optimal benefit-risk profile in these trials.
Mounjaro's SURMOUNT trials evaluated different dose levels, with higher doses generally showing greater weight loss but also increased side effects. However, comparing Wegovy vs Mounjaro doses head-to-head isn't straightforward as these trials used different patient populations, endpoints, and methodologies. Both treatments have shown cardiovascular benefits in their respective trials, with Wegovy's SELECT trial demonstrating 20% reduction in major cardiovascular events.
How Wegovy Works Through Its Dose Escalation
Wegovy functions as a GLP-1 receptor agonist, mimicking the natural incretin hormone that regulates blood sugar and appetite. The gradual dose escalation from 0.25mg to 2.4mg allows your body to adjust to increased GLP-1 receptor activation, which slows gastric emptying and enhances satiety signals to the brain. This mechanism helps reduce appetite and promotes feeling full after smaller meals, potentially reducing food cravings through effects on brain appetite centres. The 16-week escalation schedule balances therapeutic effectiveness with tolerability, as higher doses typically increase both weight loss potential and gastrointestinal side effects. Each dose level serves a specific purpose in building tolerance while achieving progressive appetite suppression and weight management benefits.
Ordering Process for Wegovy vs Mounjaro Doses
Starting either treatment through EverydayMeds begins with our 3-minute online clinical assessment covering your medical history, current medications, and weight management goals. Our qualified prescribers review your assessment within standard 3 working days (or 24 hours with express service) to determine which treatment and starting dose may be appropriate for your individual circumstances. Once approved, your prescribed dose ships via next-day delivery using our temperature-controlled cold-chain system to maintain medication integrity. Our clinical team remains available throughout your treatment journey to discuss dose adjustments, side effect management, and treatment progression. Both Wegovy and Mounjaro require ongoing prescriber oversight, with regular reviews to assess treatment response and determine if dose escalation or maintenance is appropriate.
Storage Considerations for Wegovy vs Mounjaro Doses
Storage requirements represent a practical difference when comparing Wegovy vs Mounjaro doses for UK patients. Both treatments require refrigeration at 2-8°C before first use, but Wegovy offers superior travel flexibility with 6 weeks room temperature storage (below 30°C) once removed from the fridge compared to Mounjaro's 21-day room temperature limit. The FlexTouch pen delivery system used by Wegovy provides consistent dose delivery across all strength levels, from the 0.25mg starter dose through 2.4mg maintenance. Each pen contains 4 doses, making dose tracking straightforward throughout the escalation schedule. Proper storage maintains medication potency and safety, particularly important given the extended treatment duration typical for both therapies.
Personalised Wegovy vs Mounjaro Doses Selection Strategy
Choosing between Wegovy vs Mounjaro doses requires individualised clinical assessment rather than a one-size-fits-all approach. Your prescriber will evaluate factors including your BMI, weight-related comorbidities, previous weight loss attempts, medication tolerance, and lifestyle factors that might influence treatment adherence. Wegovy's gentler starting dose (0.25mg) may suit patients concerned about initial side effects, while some patients might prefer Mounjaro's different mechanism of action targeting both GIP and GLP-1 receptors.
Your treatment response to initial doses will guide subsequent decisions about dose escalation timing and target maintenance levels. Some patients achieve their weight management goals on lower doses, while others may require full escalation to maximum approved doses. Both treatments are available from EverydayMeds with ongoing clinical support to optimise your individual dosing strategy based on treatment response, side effect profile, and weight management progress over time.
Start Your Wegovy vs Mounjaro Doses Assessment Today
Both Wegovy and Mounjaro represent evidence-based approaches to prescription weight loss, each with distinct dosing advantages for different patient needs. Our experienced clinical team at EverydayMeds (GPhC #9012878) can guide you through the Wegovy vs Mounjaro doses decision based on your individual medical profile and treatment preferences. Complete our confidential 3-minute assessment to begin your personalised evaluation, with new customer discount code FIRST40 and returning customer code DOSE25 applied at checkout. Visit https://everydaymeds.co.uk/collections/wegovy to start your clinical assessment and discover which prescription weight loss approach may support your health journey. Remember that both treatments work best as part of a comprehensive weight management programme including dietary changes and increased physical activity, with ongoing medical supervision throughout your treatment.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
